Researchers report that just four months of hormonal therapy before and with standard external beam radiation therapy slowed cancer growth by as much as eight years — especially the development of bone metastases — and increased survival in older men with potentially aggressive prostate cancer. This “neoadjuvant” hormonal therapy may allow men most at risk of developing bone metastases avoid long-term hormonal therapy later on.